0.074
0.00 (-1.33%)
| Penutupan Terdahulu | 0.075 |
| Buka | 0.074 |
| Jumlah Dagangan | 209,285 |
| Purata Dagangan (3B) | 626,847 |
| Modal Pasaran | 45,063,264 |
| Harga / Jualan (P/S) | 2.15 |
| Harga / Buku (P/B) | 1.41 |
| Julat 52 Minggu |
| Margin Keuntungan | -83.97% |
| Margin Operasi (TTM) | -136.14% |
| EPS Cair (TTM) | -0.030 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 147.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 9.72% |
| Nisbah Semasa (MRQ) | 2.17 |
| Aliran Tunai Operasi (OCF TTM) | -6.66 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -7.32 M |
| Pulangan Atas Aset (ROA TTM) | -24.29% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.42% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (AU) | Bercampur | Bercampur |
| Diagnostics & Research (Global) | Menaik | Bercampur | |
| Stok | MICROBA FPO [MAP] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -1.0 |
| Purata | 0.25 |
|
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are; Testing Services and Supplements which derives key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 47.43% |
| % Dimiliki oleh Institusi | 24.22% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |